Business
Alnylam Announces Changes to its Board of Directors
− Appoints Dr. Olivier Brandicourt, Former CEO of Sanofi and Global Pharmaceutical Industry Leader − − Announces Retirement of Dr. Paul Schimmel, an Alnylam
About this update from Alnylam Pharmaceuticals, Inc.
[{"type":"text","content":"\n− Appoints Dr. Olivier Brandicourt, Former CEO of Sanofi and Global Pharmaceutical Industry Leader −\n\n\n− Announces Retirement of Dr. Paul Schimmel, an Alnylam Co-founder, After Nearly Eighteen Years of Service −\n\n CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nAlnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced the appointment of Dr. Olivier Brandicourt to its Board of Directors effective March 2, 2020. Dr. Brandicourt served as Chief Executive Officer and a member of the Board of Directors of Sanofi from 2015 to 2019. Prior to that he was CEO and chair of Bayer HealthCare from 2013 to 2015, and spent 13 years at Pfizer, including as a member of its Executive Leadership Team and President and General Manager of the Emerging Markets and Established Products business units, amongst other roles.\n\n\nIn addition, Alnylam announces today the retirement of Dr. Paul Schimmel from the Board effective upon the conclusion of his current term at the Annual Meeting of Alnylam stockholders in 2020. Dr. Schimmel, Hahn Professor of Molecular Medicine at Scripps Research and MacArthur Professor Emeritus at MIT, is also a member of the National Academy of Sciences, National Academy of Medicine, American Philosophical Society, and American Academy of Arts and Sciences. Schimmel co-founded Alnylam where he served on the Board of Directors and Scientific Advisory Board since the Company’s founding in 2002. Following his retirement from the Board of Directors, Dr. Schimmel will continue to serve on the Company’s Scientific Advisory Board.\n\n\n“We are honored to welcome Olivier to our Board of Directors at this exciting point in Alnylam’s history. Olivier’s past leadership in three leading pharmaceutical companies and extensive global commercial experience will provide invaluable perspective to our Board as Alnylam continues to launch ONPATTRO, introduces GIVLAARI around the world, and advances additional late-stage development programs on the path to financial self-sustainability,” said John Maraganore, Ph.D. Chief Executive Officer of Alnylam. “We very much look forward to the experience Olivier will bring as we continue to advance innovative RNAi therapeutics intended to transform the lives of patients with serious, and often highly debilitating, conditions.”\n\n\n“I’m very pleased to become a director of ...